Skip to main content

Advertisement

SpringerLink
Log in

Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Survivin is a member of the inhibitor of apoptosis protein family. Gliomas and many other tumors express survivin at high levels; whereas, normal fully differentiated cells generally do not. Therefore, survivin represents a tumor-specific target for cancer vaccine therapy. It has been shown that it is possible to produce a MHC-I-restricted cellular immunologic response to survivin vaccines. To study differences in immunogenicity between murine and human survivin proteins, we vaccinated C57BL/6 mice with bone marrow dendritic cells (BMDC) transfected with expression vectors containing the murine and human survivin genes. Mice vaccinated with BMDCs expressing a truncated human survivin protein developed cytotoxic T lymphocyte to subcutaneous GL261 glioma cells and exhibited prolonged tumor-free survival compared to mice vaccinated with BMDCs transfected with vector alone (P<0.01). While mice challenged with intracerebral GL261 cells had increased survival, no cures were observed. In contrast, vaccinated mice that fully resisted subcutaneous tumor challenge were rendered resistant to intracerebral GL261 re-challenge. BMDCs transfected with the full-length human survivin molecule were significantly more effective at prolonging survival than BMDCs expressing the full-length murine survivin gene (P=0.0175). Therefore, xenogeneic differences between human and murine sequences might be exploited to develop more immunogenic tumor vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Moscatello DK, Ramirez G, Wong AJ (1997) A naturally occurring mutant epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57:1419–1424

    PubMed  CAS  Google Scholar 

  2. Heimberger AB, Crotty LE, Archer GE et al (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9:4247–4254

    PubMed  CAS  Google Scholar 

  3. Ciesielski MJ, Kazim L, Barth RF, Fenstermaker RA (2005) Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 54:107–119

    Article  PubMed  CAS  Google Scholar 

  4. Prins RM, Odesa SK, Liau LM (2003) Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63:8487–8491

    PubMed  CAS  Google Scholar 

  5. Adida C, Crotty PL, McGrath J et al (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–49

    PubMed  CAS  Google Scholar 

  6. Kajiwara Y, Yamasaki F, Hama S et al (2003) Expression of survivin in astrocytic tumors. Cancer 97:1077–1083

    Article  PubMed  Google Scholar 

  7. Sasaki T, Lopes MB, Hankins GR, Helm GA (2002) Expression of survivin an inhibitor of apoptosis protein in tumors of the nervous system. Acta Neuropathol (Berl) 104:105–109

    Article  CAS  Google Scholar 

  8. Chakravarti A, Noll E, Black P et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20:1063–1068

    Article  PubMed  CAS  Google Scholar 

  9. Islam A, Kageyama H, Takada N et al (2000) A high expression of survivin mapped to 17q25 is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19:617–623

    Article  PubMed  CAS  Google Scholar 

  10. Satoh K, Kaneko K, Hirota M et al (2001) T expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271–278

    Article  PubMed  CAS  Google Scholar 

  11. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54

    Article  PubMed  CAS  Google Scholar 

  12. Overwijk WW, Tsung A, Irvine KR et al (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive tumoricidal T cells using high-affinity altered peptide ligand. J Exp Med 188:277–286

    Article  PubMed  CAS  Google Scholar 

  13. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:2445–2452

    Article  CAS  Google Scholar 

  14. Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 4:459–473

    Article  Google Scholar 

  15. Patel AK, Boyd PN (1995) An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. J Immunol Methods 184(1):29–38

    Article  PubMed  CAS  Google Scholar 

  16. Liau LM, Black KL, Martin NA et al (2000) Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Neurosurg Focus 9:8

    Article  Google Scholar 

  17. Yu JS, Wheeler CJ, Zeltzer PM et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847

    PubMed  CAS  Google Scholar 

  18. Yu JS, Liu G, Ying H et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4999

    Article  PubMed  CAS  Google Scholar 

  19. Kikuchi T, Akasaki Y, Irie M et al (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344

    Article  PubMed  CAS  Google Scholar 

  20. Zhao J, Tenev T, Martins LM et al (2000) The ubiquitin-proteosome pathway regulates survivin degradation in a cell-cycle dependent manner. J Cell Sci 113:4363–4371

    PubMed  CAS  Google Scholar 

  21. Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584

    Article  PubMed  CAS  Google Scholar 

  22. Fortugno P, Wall NR, Giodini A et al (2002) Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115:575–585

    PubMed  CAS  Google Scholar 

  23. Tamm I, Wang Y, Sausville E et al (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95) Bax caspases and anticancer drugs. Cancer Res 58:5215–5220

    Google Scholar 

  24. Conway EM, Pollefeyt S, Cornelissen J et al (2000) Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95:1435–1442

    PubMed  CAS  Google Scholar 

  25. Shin S, Sung BJ, Cho Y et al (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117–1123

    Article  PubMed  CAS  Google Scholar 

  26. Fududa S, Mantel CR, Pelus LM (2004) Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1 dependent and independent pathways. Blood 103:120–127

    Article  PubMed  CAS  Google Scholar 

  27. Suzuki A, Hayashida M, Ito T et al (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16INK4a and Cdk2/Cyclin E complex activation. Oncogene 19:3225–3334

    Article  PubMed  CAS  Google Scholar 

  28. Grossman D, Kim PJ, Schechner JS, Altieri DC (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98:635–640

    Article  PubMed  CAS  Google Scholar 

  29. Mesri M, Wall NR, Li J et al (2001) Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108:981–990

    Article  PubMed  CAS  Google Scholar 

  30. Xiang R, Mizutani N, Luo Y et al (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65:553–561

    PubMed  CAS  Google Scholar 

  31. Zeis M, Siegel S, Wagner A et al (2003) A generation of cytotoxic responses in mice and human individually against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170:5391–5397

    PubMed  CAS  Google Scholar 

  32. Andersen MH, Pedersen LO, Becker JC, Straten P (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61:869–872

    PubMed  CAS  Google Scholar 

  33. Schmitz M, Diestelkoetter P, Weigle B et al (2000) Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60:4845–4849

    PubMed  CAS  Google Scholar 

  34. Yamanaka R, Yajima N, Abe T et al (2003) Dendritic cell-based glioma immunotherapy. Int J Oncol 23:5–15

    PubMed  CAS  Google Scholar 

  35. Yang L, Ng KY, Lillehei KO (2003) Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10:138–147

    PubMed  Google Scholar 

  36. Ehtesham M, Black KL, Yu JS (2004) Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11:192–207

    PubMed  Google Scholar 

  37. Dunn GP, Bruce AT, Ikeda H (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998

    Article  PubMed  CAS  Google Scholar 

  38. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:2445–2452

    Article  CAS  Google Scholar 

  39. Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 4:459–473

    Article  Google Scholar 

  40. Ni HT, Spellman SR, Jean WC et al (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1–9

    Article  PubMed  CAS  Google Scholar 

  41. Aoki H, Mizuno M, Natsume A et al (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50:463–468

    Article  PubMed  CAS  Google Scholar 

  42. Gordan JD, Vonderheide RH (2002) Universal tumor antigens as targets for immunotherapy. Cytotherapy 4:317–327

    Article  PubMed  CAS  Google Scholar 

  43. Altieri DC (2003) Survivin and apoptosis control. Adv Cancer Res 88:31–52

    Article  PubMed  CAS  Google Scholar 

  44. O’Connor DS, Schechner JS, Adida C et al (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156:393–398

    PubMed  CAS  Google Scholar 

  45. Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542–547

    Article  PubMed  CAS  Google Scholar 

  46. Andersen MH, Pedersen LO, Capeller B et al (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964–5968

    PubMed  CAS  Google Scholar 

  47. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH (2004) Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 3(2):173–179

    PubMed  CAS  Google Scholar 

  48. Fenstermaker RA, Ciesielski MJ (2004) Immunotherapeutic strategies for malignant gliomas. Cancer Control 11:181–191

    PubMed  Google Scholar 

  49. Hawkins WG, Gold JS, Dyall R (2000) Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128:273–280

    Article  PubMed  CAS  Google Scholar 

  50. Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S (2005) Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol 174:7104–7110

    PubMed  CAS  Google Scholar 

  51. Kieber-Emmons TB, Monzavi-Karbassi B, Wang P et al (2000) Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J Immunol 165:623

    PubMed  CAS  Google Scholar 

  52. Cunto-Amesty GP, Luo B, Monzavi-Karbassi A et al (2003) Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens. Cell Mol Biol 49:245

    PubMed  CAS  Google Scholar 

  53. Chapman PBD, Wu G, Ragupathi S et al (2004) Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10:4717

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH 5R21NS049309–02, NIH 5P30CA16056-29, the Roswell Park Alliance Foundation and the Linda Scime Fund.

Author information

Authors and Affiliations

  1. Departments of Neurosurgery and Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA

    Michael J. Ciesielski, Lisa Apfel, Tara A. Barone, Carla A. Castro, Tina C. Weiss & Robert A. Fenstermaker

Authors
  1. Michael J. Ciesielski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Apfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tara A. Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carla A. Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tina C. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert A. Fenstermaker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Ciesielski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ciesielski, M.J., Apfel, L., Barone, T.A. et al. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55, 1491–1503 (2006). https://doi.org/10.1007/s00262-006-0138-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-006-0138-6

Keywords

Search

Navigation